| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 146, 310-316, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
RJ Playford, AM Hanby, K Patel and J Calam
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.
Gastrointestinal epithelia contain a powerful protease inhibitor called pancreatic secretory trypsin inhibitor (PSTI). Patients with inflammatory bowel disease have changes in mucus structure suggestive of increased proteolysis. We therefore examined the distribution and concentration of PSTI in the colon of normal subjects and patients with inflammatory bowel disease. In normal subjects (N = 12), mucosal levels of PSTI were approximately 200 ng/mg protein in all regions of the colon and was localized to goblet and endocrine cells. Mucosal PSTI levels in the (affected) left side of the colon of patients with active (N = 12) or quiescent (N = 10) ulcerative colitis were reduced (approximately 80% of control in descending colon, 55% of control in sigmoid colon, and 50% of control in rectum, all P < 0.01), whereas levels in the (unaffected) right side of the colon were normal. PSTI levels were also reduced to approximately 65% of control in colonic tissue affected by Crohn's disease (N = 6, P = 0.01) and immunostaining showed PSTI positivity within the ulcer-associated cell lineage. As the mucous layer is important in preserving mucosal integrity, our finding of prolonged reduction in mucosal PSTI levels after an episode of ulcerative colitis probably represents a long-term reduction in a mucosal defense mechanisms that could lead to increased susceptibility to episodes of inflammation.
This article has been cited by other articles:
 |
|
 |
|
  T. Marchbank, A. Mahmood, A. J. Fitzgerald, J. Domin, M. Butler, R. A. Goodlad, G. Elia, H. M. Cox, D. A. van Heel, S. Ghosh, et al. Human Pancreatic Secretory Trypsin Inhibitor Stabilizes Intestinal Mucosa against Noxious Agents Am. J. Pathol., November 1, 2007; 171(5): 1462 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cario, D. T. Golenbock, A. Visintin, M. Runzi, G. Gerken, and D. K. Podolsky Trypsin-Sensitive Modulation of Intestinal Epithelial MD-2 as Mechanism of Lipopolysaccharide Tolerance J. Immunol., April 1, 2006; 176(7): 4258 - 4266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jacob, P.-C. Yang, D. Darmoul, S. Amadesi, T. Saito, G. S. Cottrell, A.-M. Coelho, P. Singh, E. F. Grady, M. Perdue, et al. Mast Cell Tryptase Controls Paracellular Permeability of the Intestine: ROLE OF PROTEASE-ACTIVATED RECEPTOR 2 AND {beta}-ARRESTINS J. Biol. Chem., September 9, 2005; 280(36): 31936 - 31948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Vergnolle CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT Gut, June 1, 2005; 54(6): 867 - 874. [Full Text] [PDF]
|
|
|
|
|
|
N. Cenac, A.-M. Coelho, C. Nguyen, S. Compton, P. Andrade-Gordon, W. K. MacNaughton, J. L. Wallace, M. D. Hollenberg, N. W. Bunnett, R. Garcia-Villar, et al. Induction of Intestinal Inflammation in Mouse by Activation of Proteinase-Activated Receptor-2 Am. J. Pathol., November 1, 2002; 161(5): 1903 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R J LONGMAN and B F WARREN Is the colonic reparative cell lineage yet to be discovered? Gut, August 1, 2000; 47(2): 307 - 308. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
